Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Head and Neck Neoplasms 121Lung Neoplasms 119Glioblastoma 118Carcinoma, Non-Small-Cell Lung 118Breast Neoplasms 105Lymphoma 102Squamous Cell Carcinoma of Head and Neck 90Central Nervous System Neoplasms 83Prostatic Neoplasms 80Leukemia 77Pancreatic Neoplasms 67Gliosarcoma 66Rectal Neoplasms 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 63Esophageal Neoplasms 63Brain Neoplasms 59Lymphoma, Large B-Cell, Diffuse 56Lymphoma, Follicular 55Lymphoma, Non-Hodgkin 49Hodgkin Disease 48Burkitt Lymphoma 46Sarcoma 43Lymphoma, Large-Cell, Immunoblastic 42Leukemia, Lymphocytic, Chronic, B-Cell 42Myelodysplastic Syndromes 37Lymphoma, Mantle-Cell 36Glioma 36Neoplasms 34Astrocytoma 34Lymphoma, B-Cell, Marginal Zone 33

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bladder Urothelial Carcinoma × Radiotherapy × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡